Company: WHWK
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001628280-25-015269
Chunk: 2

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 8
Chunk 2
---
ates and chargebacks by developing an independent estimate utilizing actual product sales and actual rebates and chargeback claims received. 

•Testing the completeness and accuracy of the historical rebate and chargeback claims received. 

/s/ BDO USA, P.C.

We have served as the Company's auditor since 2017.

San Diego, California

March 27, 2025

116

WHITEHAWK THERAPEUTICS, INC.

Consolidated Balance Sheets

(in thousands, except share data and par value)

Year Ended December 31,20242023AssetsCurrent assets:Cash and cash equivalents$28,670 $62,888 Short-term investments18,567 45,957 Accounts receivable, net5,903 5,488 Inventory5,311 6,427 Prepaid expenses and other current assets2,836 3,826 Total current assets61,287 124,586 Property and equipment, net6,846 4,802 Operating lease right-of-use assets787 1,169 Other assets1,399 1,866 Total assets$70,319 $132,423 Liabilities and stockholders’ equityCurrent liabilities:Accounts payable$2,159 $5,898 Accrued liabilities14,647 14,306 Operating lease liabilities, current portion268 434 Due to licensor payable (Note 7)— 5,757 Total current liabilities17,074 26,395 Operating lease liabilities, net of current portion565 833 Other liabilities202 — Total liabilities17,841 27,228 Commitments and contingencies (Note 13)Stockholders’ equity:Preferred stock, $0.0001 par value, 10,000,000 shares authorized; no shares issued and outstanding as of December 31, 2024 and 2023— — Common stock, $0.0001 par value, 300,000,000 shares authorized; 24,680,708 and 24,554,205 shares issued and outstanding as of December 31, 2024 and 2023, respectively2 2 Additional paid-in capital385,114 374,129 Accumulated other comprehensive income16 27 Accumulated deficit(332,654)(268,963)Total stockholders’ equity52,478 105,195 Total liabilities and stockholders’ equity$70,319 $132